The present invention relates to a method of diagnosing whether a subject has, or is at risk for developing, pancreatic cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an increase in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer, wherein the type of pancreatic cancer is a pancreatic endocrine tumor (PET), and the at least one miR gene product is selected from the group consisting of: miR-103, miR-107, miR-125a, miR-99a, miR-99b, miR-125b-1, miR-342, miR-130a, miR-100, miR-132, miR-129-2, miR-125b-2 and a combination thereof. The invention also relates to a probe for hybridization comprising a miRNA selected from the above group.
